Mankind Pharma Share Price: 11.7% CAGR in 3 Years as the 2023 Listing Takes On Sun Pharma, Lupin and Cipla
- November 4, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Mankind Pharma Share Price: 11.7% CAGR in 3 Years as the 2023 Listing Takes On Sun Pharma, Lupin and Cipla
Mankind Pharma previous close Rs 2,475. 3-year CAGR 11.7%. Up 1.4x since 3 Nov 2023. ROE 12.76%. Market cap Rs 1,02,315 crore.
Quick Answer
The Mankind Pharma share price closed at Rs 2,475 on 3 November 2026, a compounded annual return of 11.7% over three years. That compares with Lupin at 19.3%, Sun Pharmaceutical Industries at 15.8% and Cipla at 5.0%. The company has a market cap of Rs 1,02,315 crore and a P/E of 45.20 against an industry P/E of 37.98.
The Mankind Pharma share price has delivered a steady compounded return since the company listed in May 2023, and its market cap of Rs 1,02,315 crore now puts it ahead of Lupin and within reach of Cipla. For a debutant of only three years, that is a meaningful place among India’s large pharma companies.
We compare its three-year CAGR with Sun Pharmaceutical Industries, Lupin and Cipla, and set all four side by side on size, valuation and return on equity. Prices are adjusted for corporate actions, so the comparison is on equal terms.
Click Here – Get Free Investment Predictions
How Much Has the Mankind Pharma Share Price Returned in 3 Years?
The Mankind Pharma stock closed at Rs 1,775.10 on 3 November 2023 and at Rs 2,475.00 on 3 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.39 lakh, which is a CAGR of 11.7%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Mankind Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Mankind Pharma share price has been shaped by two forces: a strong consumer healthcare franchise that sells directly to households, and a growing portfolio of prescription brands sold through doctors.
Mankind Pharma vs Lupin, Sun Pharmaceutical Industries and Cipla: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 3 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 3 November 2026.
| Company | Close on 3 Nov 2023 | Previous close (3 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Lupin | Rs 1,186.55 | Rs 2,015.90 | 1.7x | 19.3% |
| Sun Pharmaceutical Industries | Rs 1,141.10 | Rs 1,769.90 | 1.6x | 15.8% |
| Mankind Pharma | Rs 1,775.10 | Rs 2,475.00 | 1.4x | 11.7% |
| Cipla | Rs 1,206.35 | Rs 1,396.90 | 1.2x | 5.0% |
The Mankind Pharma stock ranks third of the four at 11.7%. It sits ahead of Cipla (5.0%). The companies ahead are Lupin (19.3%) and Sun Pharmaceutical Industries (15.8%). The pharma group has performed unevenly over three years, which is normal in a sector where product launches, regulatory outcomes and currency all affect earnings. Mankind sits in the middle of the pack with a steady rather than spectacular return.
Look at the Mankind Pharma share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Rs 4,25,150 crore | 38.70 | 37.98 | 13.79% | 0.04 |
| Cipla | Rs 1,12,472 crore | 39.41 | 37.98 | 8.18% | 0.02 |
| Mankind Pharma | Rs 1,02,315 crore | 45.20 | 37.98 | 12.76% | 0.31 |
| Lupin | Rs 92,007 crore | 16.57 | 37.98 | 23.76% | 0.29 |
By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,25,150 crore, while the Mankind Pharma stock stands at Rs 1,02,315 crore, about 24% of that size. On earnings, Mankind Pharma shares trade at a P/E of 45.20 against an industry P/E of 37.98, a premium of about 19%, which signals that the market expects faster earnings growth. Peer multiples are Lupin at 16.57, Sun Pharmaceutical Industries at 38.70 and Cipla at 39.41.
Return on equity is 12.76% for the Mankind Pharma stock, which ranks third among the four, and debt to equity stands at 0.31. Trailing EPS is Rs 54.80. Pharma valuations vary widely with the mix of domestic branded business, exports and speciality products, so comparing P/E across the group is most useful when read together with ROE.
What Is Driving the Mankind Pharma Stock?
Mankind Pharma is known for consumer health brands such as Manforce, Prega News, Unwanted-21 and Gas-O-Fast, alongside a large chronic and acute prescription portfolio. Most of its revenue comes from the domestic market, where it has built a field force that reaches deep into smaller towns.
The company widened its range after buying Bharat Serums and Vaccines, which added women’s health, critical care and fertility products. The acquisition brought scale in hospital-led categories where Mankind was previously smaller.
Investors following the Mankind Pharma share price track domestic growth against the pharma market, the integration and margin of the acquired business, and the rate at which newer brands scale.
How the Established Players Stack Up
Sun Pharmaceutical Industries is the largest pharma company in India by market cap at Rs 4,25,150 crore. It compounded at 15.8% a year, trades at a P/E of 38.70 and earns an ROE of 13.79%.
Lupin has the strongest return profile of the group, with an ROE of 23.76% and a P/E of 16.57, the lowest among the four. It compounded at 19.3% a year.
Cipla is slightly larger than Mankind, with a market cap of Rs 1,12,472 crore. It compounded at 5.0% a year and carries almost no debt, with a debt to equity ratio of 0.02.
What Should Investors Track Next?
Three things to follow on the Mankind Pharma share price. First, quarterly growth against the Indian pharma market. Second, the margin of the Bharat Serums business as integration progresses. Third, the pace at which new brands reach scale.
The P/E of 45.20 sits above the industry average of 37.98, which means the market already expects steady growth. Pharma earnings can also swing on regulation and pricing, so a three-year CAGR is only part of the picture.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Mankind Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Mankind Pharma share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Mankind Pharma share price and compare pharma stocks live.
A New Pharma Name in the Big League
The Mankind Pharma share price compounded at 11.7% a year, ahead of Cipla at 5.0% and behind Sun Pharma at 15.8% and Lupin at 19.3%. Mankind is now larger by market cap than Lupin and close to Cipla.
Lupin offers the strongest returns on equity and the lowest multiple, Sun offers scale, and Mankind offers consumer brands and a domestic growth engine. Look at valuation and ROE together before deciding.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Mankind Pharma share price today?
Ans. Mankind Pharma closed at Rs 2,475 on 3 November 2026, according to NSE data. It has a market cap of Rs 1,02,315 crore and a P/E of 45.20. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Mankind Pharma stock?
Ans. Mankind Pharma delivered a price CAGR of 11.7% over three years, moving from Rs 1,775.10 on 3 November 2023 to Rs 2,475.00 on 3 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Mankind Pharma better than Sun Pharma or Cipla?
Ans. The Mankind Pharma stock compounded at 11.7%, ahead of Cipla at 5.0% and behind Sun Pharma at 15.8%. Sun is much larger by market cap, while Cipla has a lower ROE of 8.18% against 12.76% for Mankind. Better depends on your priorities.
What does Mankind Pharma do?
Ans. Mankind Pharma is an Indian pharmaceutical company with consumer health brands such as Manforce and Prega News and a large prescription portfolio. It expanded its range by acquiring Bharat Serums and Vaccines.
Is the Mankind Pharma stock debt free?
Ans. The debt to equity ratio of the Mankind Pharma stock is 0.31 and its return on equity is 12.76%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Mankind Pharma expensive compared with the industry?
Ans. Mankind Pharma trades at a P/E of 45.20 against an industry P/E of 37.98. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Lupin delivered the highest three-year CAGR at 19.3%, followed by Sun Pharmaceutical Industries at 15.8%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.
